Glucosamine Does Not Increase Dementia Risk
Based on the highest quality recent evidence, glucosamine supplementation does not increase the risk of developing dementia in older adults taking it for osteoarthritis—in fact, emerging research suggests it may be associated with a reduced risk of certain dementia subtypes.
Key Evidence on Glucosamine and Dementia
The most recent and rigorous study addressing this question directly found no association between glucosamine use and incident dementia or Parkinson's disease 1. This 2024 prospective cohort study of approximately 290,000 middle- to old-aged UK Biobank participants followed for a median of 9-10 years found hazard ratios of 1.06 (95% CI: 0.99-1.14) for dementia and 0.97 (95% CI: 0.86-1.09) for Parkinson's disease—essentially no increased risk.
Potentially Protective Effects
Interestingly, other recent high-quality studies suggest glucosamine may actually be protective against certain dementia types:
A 2023 cohort and Mendelian randomization study of 214,945 participants found glucosamine use was associated with reduced risk of vascular dementia (HR 0.82; 95% CI: 0.70-0.96), though not Alzheimer's disease 2
Another 2023 study using both observational and Mendelian randomization approaches found hazard ratios of 0.84 for all-cause dementia, 0.83 for Alzheimer's disease, and 0.74 for vascular dementia among glucosamine users 3
The protective association appeared stronger in participants under 60 years and was independent of APOE genotype 3
Clinical Context: Glucosamine for Osteoarthritis
It's important to note that while glucosamine poses no dementia risk, current clinical guidelines strongly recommend against its use for osteoarthritis due to lack of efficacy:
The 2020 ACR/Arthritis Foundation guideline strongly recommends against glucosamine for knee, hip, and hand OA, citing lack of clinically important benefits over placebo when examining studies with lowest risk of bias 4
The 2014 AAOS guideline similarly does not recommend glucosamine for knee osteoarthritis 5
The 2008 NICE guidance states glucosamine products are not recommended 6
Important Caveats
Common pitfall: Patients often perceive glucosamine as effective despite evidence to the contrary, and many continue using it. The key message is that while it lacks efficacy for joint symptoms, it does not pose cognitive harm.
Safety profile: Glucosamine has low toxicity, though some patients may experience elevations in serum glucose levels 4. This metabolic effect should be monitored in diabetic patients, but it does not translate to dementia risk.
Bottom Line
You can reassure older adults that glucosamine supplementation (approximately 1500 mg daily) does not increase dementia risk. The most recent large-scale prospective evidence shows no association, and emerging data even suggests potential protective effects against vascular dementia. However, given the strong evidence against its efficacy for osteoarthritis symptoms, alternative evidence-based treatments (exercise, weight loss, NSAIDs, intra-articular corticosteroids) should be prioritized for joint pain management 4.